UK Begins Brexit Inquiry On Devices, Pharma Supplies
In a busy week for Brexit watchers, the UK government has initiated an inquiry into the effects of future regulatory systems that will potentially impact medical technology and other health-care products in the UK after the country has left the EU.
You may also be interested in...
Germany's CDU leader Angela Merkel secured her fourth term as chancellor, but chastened by an election result that saw many of her 2013 voters turn to the liberals and far right, her hand is weakened. Indeed, the EU's rock of political stability has sprung many a surprise in delivering a 2017 election result that will give businesses a sense both of unease and promise, with the re-emergence of the liberal and business-focused FDP.
The future regulatory outlook for the UK after the country leaves the EU has not been clear during discussions to date. Now medtech industry associations have spoken out. They warn divergence will hit patient safety and must be avoided.
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.